RGC (Regencell Bioscience Holdings) Total Operating Expense: $7.13 Mil (TTM As of Dec. 2025)


RGC Regencell Bioscience Holdings Ltd RGC
34 GF Score
Price $6.13
! 2 Warning Signs
View Full Analysis

What is Regencell Bioscience Holdings Total Operating Expense?

Regencell Bioscience Holdings RGC -3.62% 34 Total Operating Expense is $7.13 Mil as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Regencell Bioscience Holdings's Total Operating Expense for the six months ended in Dec. 2025 was $5.34 Mil. Regencell Bioscience Holdings's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $7.13 Mil.

Regencell Bioscience Holdings Total Operating Expense Related Terms

Regencell Bioscience Holdings Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Regencell Bioscience Holdings's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings Total Operating Expense Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial 1.38 7.62 6.27 4.74 3.77

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.31 2.43 1.98 1.79 5.34
RGC
34GF Score
Regencell Bioscience Holdings Ltd RGC
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regencell Bioscience Holdings Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $7.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $7.13 Mil mean?
Regencell Bioscience Holdings (RGC) has a Total Operating Expense of $7.13 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Regencell Bioscience Holdings and its competitors.
Is Regencell Bioscience Holdings' Total Operating Expense too high?
Regencell Bioscience Holdings' current Total Operating Expense is $7.13 Mil. Overall, Regencell Bioscience Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Total Operating Expense compare to SUPN and BCRX?
Regencell Bioscience Holdings' Total Operating Expense of $7.13 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Regencell Bioscience Holdings and its competitors. Regencell Bioscience Holdings's current Total Operating Expense is $7.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Total Operating Expense of $7.13 Mil. The current Total Operating Expense is $7.13 Mil. Regencell Bioscience Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Total Operating Expense is $7.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regencell Bioscience Holdings Business Description

Address 29 Leighton Road, 9th Floor, Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
34GF Score

Get the complete analysis for RGC

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.13
Price